NextCure Inc expected to post a loss of 63 cents a share - Earnings Preview
Brief: Nextcure Announces Initiation Of Phase 1B/2 Trial To Evaluate NC410 With Keytruda
Brief: Nextcure Provides Business Update And Reports Second Quarter 2022 Financial Results
U.S. RESEARCH ROUNDUP-Eli Lilly, Gilead Sciences, Upwork
NextCure Inc reports results for the quarter ended in March - Earnings Summary
Brief: NextCure Provides Business Update And Reports First Quarter 2022 Financial Results
NextCure Inc expected to post a loss of 67 cents a share - Earnings Preview
Brief: Nextcure And The National Cancer Institute Announce Preclinical Data In Journal Of Clinical Investigation
NextCure Inc reports results for the quarter ended in December - Earnings Summary
Brief: NextCure Reports Q4 and Full Year 2021 Financial Results
NextCure Inc expected to post a loss of 67 cents a share - Earnings Preview
NextCure Inc reports results for the quarter ended in September - Earnings Summary
Brief: NextCure Reports Third Quarter 2021 Financial Results
NextCure Inc expected to post a loss of 67 cents a share - Earnings Preview
Brief: NextCure Announces Publication Of Preclinical Data For NC410
NextCure Inc reports results for the quarter ended in June - Earnings Summary
Brief: NextCure Reports Second Quarter 2021 Financial Results
NextCure Inc expected to post a loss of 61 cents a share - Earnings Preview
Brief: NextCure Initiates Phase 1/2 Clinical Trial Of NC762 For Solid Tumors